Evidence map›Paper›PMID 38854217›Full record

ArticleCureus2024

Extremely Longitudinally Extensive Transverse Myelitis in a Patient With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

So Okubo, Toshiyuki Kakumoto, Masahiko Tsujita, Kyosuke Muramatsu, Sho Fujiwara, Masashi Hamada, Wataru Satake, Tatsushi Toda

Abstract readCase Reports
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Movement Disorders in MOGAD: A Systematic Review.Medicina (Kaunas, Lithuania) · 2026
    Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

So OkuboNeurology, University of Tokyo Graduate School of Medicine, Tokyo, JPN.
Toshiyuki KakumotoNeurology, University of Tokyo Graduate School of Medicine, Tokyo, JPN.
Masahiko TsujitaNeurology, University of Tokyo Graduate School of Medicine, Tokyo, JPN.
Kyosuke MuramatsuNeurology, University of Tokyo Graduate School of Medicine, Tokyo, JPN.
Sho FujiwaraNeurology, University of Tokyo Graduate School of Medicine, Tokyo, JPN.
Masashi HamadaNeurology, University of Tokyo Graduate School of Medicine, Tokyo, JPN.
Wataru SatakeNeurology, University of Tokyo Graduate School of Medicine, Tokyo, JPN.
Tatsushi TodaNeurology, University of Tokyo Graduate School of Medicine, Tokyo, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Longitudinally extensive myelitis with 15 or more vertebrae in length is extremely rare, with limited evidence regarding clinical features and therapeutic response. We report a case of a 29-year-old male patient with extremely longitudinally extensive myelitis ultimately diagnosed as myelin oligodendrocyte glycoprotein-associated disease (MOGAD). The patient presented with an acute onset of meningismus, limb weakness, sensory disturbance below the C5 level, ataxia, and urinary retention. T2-weighted imaging on MRI showed an extremely longitudinally extensive spinal cord lesion ranging from C2 to the medullary conus, together with a left pontine lesion. Positive anti-myelin oligodendrocyte glycoprotein antibodies were serologically detected, which led to the diagnosis of MOGAD. Intravenous methylprednisolone followed by 1 mg/kg oral prednisolone with taper resulted in complete symptomatic and radiological resolution. The striking complete resolution despite the symptomatic and radiological severity observed in this case has been described in a few previously reported MOGAD cases. Extremely longitudinally extensive myelitis with excellent therapeutic response may be a characteristic presentation of MOGAD.

Indexed as

anti-mog antibodylongitudinally extensive transverse myelitismog associated antibody disease (mogad)neuro-immunologyspinal cord diseases

Identifiers

PMID38854217
PMCPMC11161715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.